IDYA catalyst calendar

IDEAYA Biosciences, Inc.

Upcoming catalysts
12
Cash runway
33.1 months
Cash & investments
$829M
Phase 3 programs
3

IDEAYA Biosciences, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors on October 15, 2026. There are 12 upcoming events on record.

Cash runway is approximately 33.1 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Upcoming catalysts

DateEventTypePhase
October 15, 2026 A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors Trial Milestone Phase 1
November 3, 2026 est. Next quarterly earnings (projected) Earnings —
January 7, 2027 Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion Trial Milestone Phase 1
January 15, 2027 IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma Trial Milestone Phase 2/Phase 3
January 29, 2027 Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions Trial Milestone Phase 1/Phase 2
April 30, 2027 (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma Trial Milestone Phase 2
July 30, 2027 A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types Trial Milestone Phase 1
April 30, 2028 A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors Trial Milestone Phase 1
July 15, 2029 A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer Trial Milestone Phase 1/Phase 2
March 30, 2030 A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors Trial Milestone Phase 1
October 15, 2030 Neoadjuvant Darovasertib in Primary Uveal Melanoma Trial Milestone Phase 3
March 15, 2034 Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma Trial Milestone Phase 3

Track IDYA alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open IDYA in the tracker

Recent history

DateEventTypePhase
August 4, 2026 Quarterly results filed (8-K) Earnings —
June 23, 2026 8-K filed: Other event Filing —
June 10, 2026 8-K filed: Other event Filing —
June 3, 2026 8-K filed: Other event Filing —
June 1, 2026 8-K filed: Reg FD disclosure, Other event Filing —
May 5, 2026 Quarterly results filed (8-K) Earnings —
May 5, 2026 8-K filed: Other event Filing —
April 13, 2026 8-K filed: Other event Filing —
April 9, 2026 8-K filed: Other event Filing —
February 17, 2026 Quarterly results filed (8-K) Earnings —
January 12, 2026 8-K filed: Reg FD disclosure Filing —
January 12, 2026 8-K filed: Other event Filing —
December 5, 2025 8-K filed: Other event Filing —
November 4, 2025 Quarterly results filed (8-K) Earnings —
October 20, 2025 8-K filed: Other event Filing —
September 8, 2025 8-K filed: Other event Filing —
September 2, 2025 8-K filed: Material agreement Corporate —
August 5, 2025 Quarterly results filed (8-K) Earnings —
June 27, 2025 8-K filed: Leadership change Corporate —
May 6, 2025 Quarterly results filed (8-K) Earnings —

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.